BRUSSELS, June 30 - U.S. generic drugmaker Mylan NV
has offered concessions in a bid to allay concerns by EU
competition regulators over its proposed $7.2-billion
acquisition of Swedish rival Meda, the European
Commission said on Thursday.
Read more
No comments:
Post a Comment